0001104659-20-065356.txt : 20200522 0001104659-20-065356.hdr.sgml : 20200522 20200522160847 ACCESSION NUMBER: 0001104659-20-065356 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20200520 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20200522 DATE AS OF CHANGE: 20200522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC CENTRAL INDEX KEY: 0001267565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37372 FILM NUMBER: 20905907 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 BUSINESS PHONE: 781-713-3699 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 FORMER COMPANY: FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC DATE OF NAME CHANGE: 20031020 8-K 1 tm2020691-1_8k.htm FORM 8-K
0001267565 false 0001267565 2020-05-19 2020-05-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 20, 2020

 

COLLEGIUM PHARMACEUTICAL, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Virginia   001-37372   03-0416362
(State or Other Jurisdiction
of Incorporation or Organization)		   (Commission
File Number)		   (IRS Employer Identification
No.)

 

100 Technology Center Drive

Suite 300

Stoughton, MA 02072

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (781) 713-3699

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.001 per share   COLL   The NASDAQ Global Select Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

 

Item 5.07        Submission of Matters to a Vote of Security Holders.

 

A total of 34,306,040 shares of the Company’s common stock were entitled to vote as of March 31, 2020, the record date for the Annual Meeting, of which 32,680,374 were present in person or by proxy at the Annual Meeting.  The following is a summary of the final voting results for each matter presented to shareholders.

 

PROPOSAL 1:

 

Election of three Class II Directors to hold office until the 2023 Annual Meeting of Shareholders.

 

Nominee  For   Against   Abstentions   Broker Non-Votes 
Joseph Ciaffoni  28,340,858   82,796   5,386   4,251,334 
Michael Heffernan, R.Ph.  27,577,693   845,831   5,516   4,251,334 
Gino Santini  26,702,728   1,720,041   6,271   4,251,334 

 

Each of the nominees was re-elected by the Company’s shareholders as Class II Directors to hold office until the 2023 Annual Meeting of Shareholders.

 

PROPOSAL 2:

 

Approval of, on an advisory basis, the compensation of the Company’s named executive officers.

 

For   Against   Abstentions   Broker Non-Votes 
27,832,853   559,829   36,358   4,251,334 

 

On an advisory basis, the Company’s shareholders approved the compensation of the Company’s named executive officers.

 

PROPOSAL 3:

 

Approval of a proposed amendment and restatement of the Company’s Second Amended and Restated Articles of Incorporation to declassify the Company’s Board of Directors.

 

For   Against   Abstentions   Broker Non-Votes 
28,374,423   23,179   31,438   4,251,334 

 

Proposal 3 was approved by the Company’s shareholders.

 

PROPOSAL 4:

 

Approval of a proposed amendment and restatement of the Company’s Second Amended and Restated Articles of Incorporation to eliminate the supermajority voting requirement for amendments to the Company’s Amended and Restated Bylaws.

 

For   Against   Abstentions   Broker Non-Votes 
28,346,087   50,925   32,028   4,251,334 

 

Proposal 4 was approved by the Company’s shareholders.

 

PROPOSAL 5:

 

Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020.

 

For   Against   Abstentions   Broker Non-Votes 
32,662,806   11,396   6,172   0 

 

Proposal 5 was approved by the Company’s shareholders.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 22, 2020 Collegium Pharmaceutical, Inc.
     
  By: /s/ Paul Brannelly
    Name: Paul Brannelly
    Title: Executive Vice President and Chief Financial Officer

 

 

 EX-101.SCH 2 coll-20200520.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 coll-20200520_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 coll-20200520_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ZIP 5 0001104659-20-065356-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-065356-xbrl.zip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end JSON 6 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2020691-1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "tm2020691-1_8k.htm" ] }, "labelLink": { "local": [ "coll-20200520_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "coll-20200520_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "coll-20200520.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "coll", "nsuri": "http://collegiumpharma.com/20200520", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2020691-1_8k.htm", "contextRef": "From2020-05-19to2020-05-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://collegiumpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2020691-1_8k.htm", "contextRef": "From2020-05-19to2020-05-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://collegiumpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } XML 7 tm2020691-1_8k_htm.xml IDEA: XBRL DOCUMENT 0001267565 2020-05-19 2020-05-20 iso4217:USD shares iso4217:USD shares 0001267565 false 8-K 2020-05-20 COLLEGIUM PHARMACEUTICAL, INC. VA 001-37372 03-0416362 100 Technology Center Drive Suite 300 Stoughton MA 02072 781 713-3699 Common stock, par value $0.001 per share COLL NASDAQ false false false false false XML 8 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://collegiumpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2020691-1_8k.htm coll-20200520.xsd coll-20200520_lab.xml coll-20200520_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover
May 20, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 20, 2020
Entity File Number 001-37372
Entity Registrant Name COLLEGIUM PHARMACEUTICAL, INC.
Entity Central Index Key 0001267565
Entity Tax Identification Number 03-0416362
Entity Incorporation, State or Country Code VA
Entity Address, Address Line One 100 Technology Center Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Stoughton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02072
City Area Code 781
Local Phone Number 713-3699
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol COLL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}